Targeted Therapy for Mesothelioma: 2026 Guide

What Is Targeted Therapy?

Targeted therapy uses drugs designed to attack specific genetic abnormalities in cancer cells. Unlike chemotherapy, which kills rapidly dividing cells indiscriminately, targeted therapies aim for precise molecular targets found primarily in tumor cells.

For mesothelioma, researchers have identified several genetic mutations that drive tumor growth. By developing drugs that interfere with these specific pathways, oncologists hope to achieve better outcomes with fewer side effects than traditional chemotherapy.

Key Genetic Targets in Mesothelioma

BAP1 Mutations

BAP1 (BRCA1-associated protein 1) is the most commonly mutated gene in mesothelioma, affecting approximately 60% of cases. BAP1 normally functions as a tumor suppressor, helping cells repair DNA damage. When BAP1 is lost:

• Cells cannot properly repair DNA damage
• Tumor growth is accelerated
• The cancer may become more aggressive

Researchers are testing drugs that exploit BAP1-deficient cells’ vulnerability, including EZH2 inhibitors such as tazemetostat, PARP inhibitors, and histone deacetylase (HDAC) inhibitors. The NCI-sponsored BAPtism trial (NCT04117880) is testing tazemetostat in BAP1-deficient mesothelioma.

NF2 Mutations

NF2 (neurofibromin 2) mutations occur in approximately 40% of mesotheliomas. NF2 regulates the Hippo signaling pathway, which controls cell growth. When NF2 is mutated, the Hippo pathway becomes dysregulated, TEAD transcription factors become overactive, and cells proliferate uncontrollably. TEAD inhibitors are designed to block this downstream effect of NF2 loss.

CDKN2A Deletions

CDKN2A is deleted in up to 70% of mesotheliomas. This gene produces proteins (p16 and p14ARF) that normally prevent uncontrolled cell division. CDK4/6 inhibitors like palbociclib (Ibrance), ribociclib (Kisqali), and abemaciclib (Verzenio) may help restore cell cycle control in tumors with CDKN2A loss, and are being evaluated in mesothelioma-specific trials.

TEAD Inhibitors: Promising New Approach

TEAD inhibitors represent one of the most promising targeted therapy developments for mesothelioma. These drugs target transcriptional enhanced associate domain (TEAD) proteins that become overactive when the Hippo pathway is disrupted.

IK-930 Clinical Trial Results

At the 2025 ESMO Congress, Ikena Oncology presented data from their Phase 1 trial of IK-930:

Outcome Measure	Result
Overall response rate	18.5% (5/27 patients)
Disease control rate	74%
Median duration of response	7.1 months
Treatment-related serious AEs	11%

The responses were seen across multiple tumor types with Hippo pathway dysfunction, including mesothelioma.

VT3989 Trial

Vivace Therapeutics is testing VT3989, another pan-TEAD inhibitor:

• Phase 1/2 trial ongoing
• Targeting NF2-mutated cancers including mesothelioma
• Preliminary data expected 2026

ODM-212 (TEADES Trial)

Orion Pharma initiated the Phase 2 TEADES trial in December 2025:

• Testing oral pan-TEAD inhibitor ODM-212
• Enrolling approximately 300 patients globally
• Targets Hippo pathway dysfunction

EZH2 Inhibitors for BAP1-Deficient Tumors

EZH2 is an enzyme that can drive cancer growth in BAP1-deficient tumors. By blocking EZH2, researchers hope to restore normal cell function.

Tazemetostat (Tazverik)

Tazemetostat is FDA-approved for certain sarcomas and is being studied in mesothelioma:

• Targets BAP1-deficient tumors
• Phase 2 trials ongoing
• May be combined with immunotherapy

ADI-PEG20: Arginine Depletion Therapy

ADI-PEG20 (pegargiminase) works differently from traditional targeted therapies. Many mesothelioma cells lack the ability to produce arginine, an essential amino acid. ADI-PEG20 depletes arginine in the bloodstream, effectively starving these cancer cells.

ATOMIC-Meso Trial Results

The Phase 3 ATOMIC-Meso trial showed remarkable results:

Outcome	ADI-PEG20 + Chemo	Chemo Alone
3-year survival	4x higher	Baseline
Progression-free survival	6 months	4.1 months
Overall survival improvement	+2 months	,

Who May Benefit from Targeted Therapy?

Targeted therapy works best when doctors can identify a specific target in your tumor. Consider targeted therapy if:

You have a confirmed genetic mutation:

• BAP1 loss (60% of cases)
• NF2 mutation (40% of cases)
• CDKN2A deletion (70% of cases)

Standard treatments have stopped working:

• After chemotherapy progression
• After immunotherapy progression
• As part of clinical trial enrollment

You’re a candidate for clinical trials:

• Adequate performance status
• No contraindications
• Tumor tissue available for genetic testing

Genetic Testing for Targeted Therapy

To determine if targeted therapy may help, genetic testing of your tumor is essential.

What Tests Are Available

Test Type	What It Shows	Turnaround
Next-generation sequencing (NGS)	Full genetic profile	2-3 weeks
Fluorescence in situ hybridization (FISH)	Specific deletions (CDKN2A)	3-5 days
Immunohistochemistry (IHC)	Protein expression (BAP1)	2-3 days

Where to Get Tested

• Major cancer centers offer comprehensive testing
• Commercial labs (Foundation Medicine, Tempus, Caris)
• Academic medical centers with mesothelioma programs

Current Clinical Trials (2026)

Several clinical trials are testing targeted therapies for mesothelioma:

Phase 1/2 Trials

Ikena Oncology’s TEAD inhibitor IK-930 is enrolling people with solid tumors showing Hippo pathway dysfunction at multiple US sites. Vivace Therapeutics’ VT3989 (NCT04665206), a pan-TEAD inhibitor, is enrolling NF2-mutated mesothelioma at US and international sites. Tazemetostat combinations with immunotherapy are enrolling people with BAP1-deficient tumors at major cancer centers including Memorial Sloan Kettering and MD Anderson.

How to Find Trials

1. ClinicalTrials.gov: Search “mesothelioma targeted therapy”
2. Your oncologist can check NCI trial databases
3. Major mesothelioma centers maintain current trial lists
4. Commercial matching services (EmergingMed, TrialJectory)

Side Effects of Targeted Therapy

Targeted therapies generally cause different side effects than chemotherapy:

Common side effects:

• Fatigue (20-40%)
• Nausea (15-25%)
• Elevated liver enzymes (10-20%)
• Skin rash (varies by drug)

Serious but less common:

• Cardiac effects (some drugs)
• Liver toxicity
• Interstitial lung disease (rare)

Most side effects are manageable and less severe than chemotherapy-related effects like blood count suppression.

Combining Targeted Therapy with Other Treatments

The future of mesothelioma treatment likely involves combining targeted therapy with:

Immunotherapy:

• TEAD inhibitors may enhance immune response
• EZH2 inhibitors being tested with checkpoint inhibitors
• Combination approaches in multiple trials

Chemotherapy:

• ADI-PEG20 approved in combination with chemotherapy
• Sequential approaches being studied

Surgery:

• Targeted therapy may help shrink tumors pre-surgery
• Post-surgery maintenance under investigation

References

Nature Reviews Clinical Oncology. (2023). BAP1 mutations in malignant mesothelioma: genomic implications for clinical management.
https://pubmed.ncbi.nlm.nih.gov/36856697/

ESMO Congress 2025. (2025). Phase 1 Study of IK-930, a First-in-Class Pan-TEAD Inhibitor, in Patients with Advanced Solid Tumors.
https://oncologypro.esmo.org/meeting-resources/esmo-congress

Journal of Clinical Oncology. (2024). Phase III ATOMIC-Meso trial of ADI-PEG20 plus chemotherapy in malignant pleural mesothelioma.
https://pubmed.ncbi.nlm.nih.gov/38728019/

Clinical Cancer Research. (2021). The Hippo pathway effector YAP is a critical target in mesothelioma.
https://pubmed.ncbi.nlm.nih.gov/33795389/

Frontiers in Oncology. (2023). Genetic alterations and treatment options for mesothelioma.
https://pubmed.ncbi.nlm.nih.gov/36890814/